The unique immune microenvironment of liver metastases: Challenges and opportunities

Kim, 2019, Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy, PLoS One, 14, e0211105, 10.1371/journal.pone.0211105 Wu, 2015, Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib, Lung Cancer, 88, 187, 10.1016/j.lungcan.2015.02.012 Wyld, 2003, Prognostic factors for patients with hepatic metastases from breast cancer, Br. J. Cancer, 89, 284, 10.1038/sj.bjc.6601038 Ansa, 2018, Evaluation of colorectal Cancer incidence trends in the United States (2000-2014), J. Clin. Med., 7, 10.3390/jcm7020022 Borner, 1999, Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer--too good to be true?, Ann. Oncol., 10, 623, 10.1023/A:1008353227103 Helling, 2014, Cause of death from liver metastases in colorectal cancer, Ann. Surg. Oncol., 21, 501, 10.1245/s10434-013-3297-7 Lautt, 2010, Resistance in the venous system, 53 Milette, 2017, Molecular pathways: targeting the microenvironment of liver metastases, Clin. Cancer Res., 23, 6390, 10.1158/1078-0432.CCR-15-1636 Williamson, 2019, The role of liver microenvironment in hepatic metastasis, Clin. Transl. Med., 8, 21, 10.1186/s40169-019-0237-6 Takemura, 2017, Role of surgical resection for non-colorectal non-neuroendocrine liver metastases, World J. Hepatol., 9, 242, 10.4254/wjh.v9.i5.242 de Ridder, 2016, Liver resection for metastatic disease; a population-based analysis of trends, Dig. Surg., 33, 104, 10.1159/000441802 Lyratzopoulos, 2007, Recent trends in liver resection surgery activity and population utilization rates in English regions, HPB (Oxford), 9, 277, 10.1080/13651820701504165 Adam, 2009, Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?, J. Clin. Oncol., 27, 1829, 10.1200/JCO.2008.19.9273 Guglielmi, 2012, How much remnant is enough in liver resection?, Dig. Surg., 29, 6, 10.1159/000335713 Robin, 2018, A contemporary update on the role of stereotactic body radiation therapy (SBRT) for liver metastases in the evolving landscape of oligometastatic disease management, Semin. Radiat. Oncol., 28, 288, 10.1016/j.semradonc.2018.06.009 Nordlinger, 2008, Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial, Lancet, 371, 1007, 10.1016/S0140-6736(08)60455-9 Nordlinger, 2013, Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial, Lancet Oncol., 14, 1208, 10.1016/S1470-2045(13)70447-9 Network, 2020 Khan, 2019, Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution, Crit. Rev. Oncol. Hematol., 143, 153, 10.1016/j.critrevonc.2019.09.001 Ohhara, 2016, Role of targeted therapy in metastatic colorectal cancer, World J. Gastrointest. Oncol., 8, 642, 10.4251/wjgo.v8.i9.642 Heinemann, 2014, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, Lancet Oncol., 15, 1065, 10.1016/S1470-2045(14)70330-4 Sandhu, 2019, Systemic treatment for metastatic colorectal cancer in the era of precision medicine, J. Surg. Oncol., 119, 564, 10.1002/jso.25421 Venook, 2017, Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal Cancer: a randomized clinical trial, JAMA, 317, 2392, 10.1001/jama.2017.7105 Douillard, 2013, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer, N. Engl. J. Med., 369, 1023, 10.1056/NEJMoa1305275 Douillard, 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study, J. Clin. Oncol., 28, 4697, 10.1200/JCO.2009.27.4860 Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N. Engl. J. Med., 359, 1757, 10.1056/NEJMoa0804385 Pietrantonio, 2015, Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis, Eur. J. Cancer, 51, 587, 10.1016/j.ejca.2015.01.054 Rowland, 2015, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer, Br. J. Cancer, 112, 1888, 10.1038/bjc.2015.173 Van Cutsem, 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N. Engl. J. Med., 360, 1408, 10.1056/NEJMoa0805019 Kopetz, 2019, Encorafenib, Binimetinib, and cetuximab in BRAF V600E-Mutated colorectal Cancer, N. Engl. J. Med., 381, 1632, 10.1056/NEJMoa1908075 Meric-Bernstam, 2019, Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study, Lancet Oncol., 20, 518, 10.1016/S1470-2045(18)30904-5 Sartore-Bianchi, 2016, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial, Lancet Oncol., 17, 738, 10.1016/S1470-2045(16)00150-9 Creasy, 2018, Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?, Surgery, 163, 1238, 10.1016/j.surg.2018.01.004 Siegel, 2017, Colorectal cancer statistics, 2017, CA Cancer J. Clin., 67, 177, 10.3322/caac.21395 Tomlinson, 2007, Actual 10-year survival after resection of colorectal liver metastases defines cure, J. Clin. Oncol., 25, 4575, 10.1200/JCO.2007.11.0833 Hu, 2019, Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018, Transl. Lung Cancer Res., 8, 1091, 10.21037/tlcr.2019.10.17 Queirolo, 2019, Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy, Semin. Cancer Biol., 59, 290, 10.1016/j.semcancer.2019.08.001 Wilky, 2019, Immune checkpoint inhibitors: the linchpins of modern immunotherapy, Immunol. Rev., 290, 6, 10.1111/imr.12766 Xu, 2020, Checkpoint inhibitor immunotherapy in kidney cancer, Nat. Rev. Urol., 17, 137, 10.1038/s41585-020-0282-3 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 Overman, 2018, Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch Repair-Deficient/Microsatellite instability-high metastatic colorectal Cancer, J. Clin. Oncol., 36, 773, 10.1200/JCO.2017.76.9901 Fang, 2013, Targeting the tumor microenvironment: from understanding pathways to effective clinical trials, Cancer Res., 73, 4965, 10.1158/0008-5472.CAN-13-0661 Jaszai, 2019, Trends and challenges in tumor anti-angiogenic therapies, Cells, 8, 10.3390/cells8091102 Vidal-Vanaclocha, 2008, The prometastatic microenvironment of the liver, Cancer Microenviron., 1, 113, 10.1007/s12307-008-0011-6 Vidal-Vanaclocha, 2011, The tumor microenvironment at different stages of hepatic metastasis Van den Eynden, 2013, The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications, Cancer Res., 73, 2031, 10.1158/0008-5472.CAN-12-3931 Bilen, 2019, Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy, BMC Cancer, 19, 857, 10.1186/s12885-019-6073-7 Shiroyama, 2018, Clinical characteristics of liver metastasis in nivolumab-treated patients with non-small cell lung Cancer, Anticancer Res., 38, 4723, 10.21873/anticanres.12779 Tumeh, 2017, Liver metastasis and treatment outcome with Anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC, Cancer Immunol. Res., 5, 417, 10.1158/2326-6066.CIR-16-0325 Lee, 2017, Relationship between liver metastases and PD-1 blockade in melanoma, J. Clin. Oncol., 35 Crispe, 2006, Cellular and molecular mechanisms of liver tolerance, Immunol. Rev., 213, 101, 10.1111/j.1600-065X.2006.00435.x Bogdanos, 2013, Liver immunology, Compr. Physiol., 3, 567, 10.1002/cphy.c120011 Tay, 2014, Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses, Proc Natl Acad Sci U S A, 111, E2540, 10.1073/pnas.1406674111 Crispe, 2009, The liver as a lymphoid organ, Annu. Rev. Immunol., 27, 147, 10.1146/annurev.immunol.021908.132629 Doherty, 2000, Innate and adaptive lymphoid cells in the human liver, Immunol. Rev., 174, 5, 10.1034/j.1600-0528.2002.017416.x Benlagha, 2002, A thymic precursor to the NK T cell lineage, Science, 296, 553, 10.1126/science.1069017 Dashtsoodol, 2017, Alternative pathway for the development of Valpha14(+) NKT cells directly from CD4(-)CD8(-) thymocytes that bypasses the CD4(+)CD8(+) stage, Nat. Immunol., 18, 274, 10.1038/ni.3668 Geissmann, 2005, Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids, PLoS Biol., 3, e113, 10.1371/journal.pbio.0030113 Gumperz, 2002, Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining, J. Exp. Med., 195, 625, 10.1084/jem.20011786 Kubes, 2018, Immune responses in the liver, Annu. Rev. Immunol., 36, 247, 10.1146/annurev-immunol-051116-052415 Mossanen, 2016, Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury, Hepatology, 64, 1667, 10.1002/hep.28682 Zhang, 2016, CCL2-CCR2 signaling promotes hepatic ischemia/reperfusion injury, J. Surg. Res., 202, 352, 10.1016/j.jss.2016.02.029 Krenkel, 2017, Liver macrophages in tissue homeostasis and disease, Nat. Rev. Immunol., 17, 306, 10.1038/nri.2017.11 Aalto, 2011, Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer, Blood, 118, 3725, 10.1182/blood-2010-09-311076 Kivi, 2009, Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate, Blood, 114, 5385, 10.1182/blood-2009-04-219253 Racanelli, 2006, The liver as an immunological organ, Hepatology, 43, S54, 10.1002/hep.21060 Tiegs, 2010, Immune tolerance: what is unique about the liver, J. Autoimmun., 34, 1, 10.1016/j.jaut.2009.08.008 Crispe, 2011, Liver antigen-presenting cells, J. Hepatol., 54, 357, 10.1016/j.jhep.2010.10.005 Klugewitz, 2002, Immunomodulatory effects of the liver: deletion of activated CD4+ effector cells and suppression of IFN-gamma-producing cells after intravenous protein immunization, J. Immunol., 169, 2407, 10.4049/jimmunol.169.5.2407 Doherty, 2016, Immunity, tolerance and autoimmunity in the liver: a comprehensive review, J. Autoimmun., 66, 60, 10.1016/j.jaut.2015.08.020 You, 2008, Mechanism of T cell tolerance induction by murine hepatic Kupffer cells, Hepatology, 48, 978, 10.1002/hep.22395 Abo, 2000, Physiological responses of extrathymic T cells in the liver, Immunol. Rev., 174, 135, 10.1034/j.1600-0528.2002.017415.x David, 2016, Combination of mass cytometry and imaging analysis reveals origin, location, and functional repopulation of liver myeloid cells in mice, Gastroenterology, 151, 1176, 10.1053/j.gastro.2016.08.024 Bamboat, 2009, Human liver dendritic cells promote T cell hyporesponsiveness, J. Immunol., 182, 1901, 10.4049/jimmunol.0803404 Goddard, 2004, Interleukin-10 secretion differentiates dendritic cells from human liver and skin, Am. J. Pathol., 164, 511, 10.1016/S0002-9440(10)63141-0 Xia, 2008, Hepatic microenvironment programs hematopoietic progenitor differentiation into regulatory dendritic cells, maintaining liver tolerance, Blood, 112, 3175, 10.1182/blood-2008-05-159921 Tokita, 2008, Poor allostimulatory function of liver plasmacytoid DC is associated with pro-apoptotic activity, dependent on regulatory T cells, J. Hepatol., 49, 1008, 10.1016/j.jhep.2008.07.028 Heymann, 2016, Immunology in the liver--from homeostasis to disease, Nat. Rev. Gastroenterol. Hepatol., 13, 88, 10.1038/nrgastro.2015.200 Ibrahim, 2012, Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver, Gastroenterology, 143, 1061, 10.1053/j.gastro.2012.06.003 Chen, 2007, Natural killer dendritic cells are an intermediate of developing dendritic cells, J. Leukoc. Biol., 81, 1422, 10.1189/jlb.1106674 Pillarisetty, 2005, Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12, J. Immunol., 174, 2612, 10.4049/jimmunol.174.5.2612 Balam, 2012, CSP--a model for in vivo presentation of Plasmodium berghei sporozoite antigens by hepatocytes, PLoS One, 7, e51875, 10.1371/journal.pone.0051875 Qian, 2001, Hepatocyte-induced apoptosis of activated T cells, a mechanism of liver transplant tolerance, is related to the expression of ICAM-1 and hepatic lectin, Transplant. Proc., 33, 226, 10.1016/S0041-1345(00)01985-0 Charles, 2013, Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway, Transplantation, 96, 17, 10.1097/TP.0b013e318294caae Jiang, 2008, Hepatic stellate cells preferentially expand allogeneic CD4+ CD25+ FoxP3+ regulatory T cells in an IL-2-dependent manner, Transplantation, 86, 1492, 10.1097/TP.0b013e31818bfd13 Hochst, 2013, Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion, J. Hepatol., 59, 528, 10.1016/j.jhep.2013.04.033 Brodt, 2016, Role of the microenvironment in liver metastasis: from pre- to prometastatic niches, Clin. Cancer Res., 22, 5971, 10.1158/1078-0432.CCR-16-0460 Keirsse, 2018, The role of hepatic macrophages in liver metastasis, Cell. Immunol., 330, 202, 10.1016/j.cellimm.2018.03.010 Costa-Silva, 2015, Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver, Nat. Cell Biol., 17, 816, 10.1038/ncb3169 Barbazan, 2017, Liver metastasis is facilitated by the adherence of circulating tumor cells to vascular fibronectin deposits, Cancer Res., 77, 3431, 10.1158/0008-5472.CAN-16-1917 Wen, 2013, Bimodal role of Kupffer cells during colorectal cancer liver metastasis, Cancer Biol. Ther., 14, 606, 10.4161/cbt.24593 Matsumura, 2014, Kupffer cells decrease metastasis of colon cancer cells to the liver in the early stage, Int. J. Oncol., 45, 2303, 10.3892/ijo.2014.2662 Timmers, 2004, Interactions between rat colon carcinoma cells and Kupffer cells during the onset of hepatic metastasis, Int. J. Cancer, 112, 793, 10.1002/ijc.20481 Kimura, 2016, The innate immune receptor Dectin-2 mediates the phagocytosis of cancer cells by Kupffer cells for the suppression of liver metastasis, Proc Natl Acad Sci U S A, 113, 14097, 10.1073/pnas.1617903113 Wang, 2000, B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis, Cancer Res., 60, 5862 McDonald, 2008, Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids, J. Exp. Med., 205, 915, 10.1084/jem.20071765 Shaul, 2018, Cancer-related circulating and tumor-associated neutrophils - subtypes, sources and function, FEBS J., 285, 4316, 10.1111/febs.14524 Mizuno, 2019, The role of tumor-associated neutrophils in colorectal Cancer, Int. J. Mol. Sci., 20, 10.3390/ijms20030529 Walsh, 2005, Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer, J. Surg. Oncol., 91, 181, 10.1002/jso.20329 Gordon-Weeks, 2017, Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2-dependent angiogenesis in mice, Hepatology, 65, 1920, 10.1002/hep.29088 Jackstadt, 2019, Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal Cancer to drive poor-prognosis subtypes and metastasis, Cancer Cell, 36, 319, 10.1016/j.ccell.2019.08.003 Steele, 2016, CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma, Cancer Cell, 29, 832, 10.1016/j.ccell.2016.04.014 Cools-Lartigue, 2013, Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis, J. Clin. Invest., 123, 3446, 10.1172/JCI67484 Giese, 2019, Neutrophil plasticity in the tumor microenvironment, Blood, 133, 2159, 10.1182/blood-2018-11-844548 Fridlender, 2009, Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN, Cancer Cell, 16, 183, 10.1016/j.ccr.2009.06.017 Rayes, 2018, Loss of neutrophil polarization in colon carcinoma liver metastases of mice with an inducible, liver-specific IGF-I deficiency, Oncotarget, 9, 15691, 10.18632/oncotarget.24593 Calon, 2012, Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation, Cancer Cell, 22, 571, 10.1016/j.ccr.2012.08.013 Calon, 2014, TGF-beta in CAF-mediated tumor growth and metastasis, Semin. Cancer Biol., 25, 15, 10.1016/j.semcancer.2013.12.008 Zhao, 2013, Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis, Hepatology, 57, 829, 10.1002/hep.26094 Freire Valls, 2019, VEGFR1(+) metastasis-associated macrophages contribute to metastatic angiogenesis and influence colorectal Cancer patient outcome, Clin. Cancer Res., 25, 5674, 10.1158/1078-0432.CCR-18-2123 Kitamura, 2010, Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model, Proc Natl Acad Sci U S A, 107, 13063, 10.1073/pnas.1002372107 Seubert, 2015, Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice, Hepatology, 61, 238, 10.1002/hep.27378 Dhanasekaran, 2020, MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity, Elife, 9 Grossman, 2018, Recruitment of CCR2(+) tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer, Oncoimmunology, 7, e1470729, 10.1080/2162402X.2018.1470729 Li, 2017, Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma, Gut, 66, 157, 10.1136/gutjnl-2015-310514 Erreni, 2016, The fractalkine-receptor Axis Improves human colorectal Cancer prognosis by limiting tumor metastatic dissemination, J. Immunol., 196, 902, 10.4049/jimmunol.1501335 Piao, 2015, Complement 5a enhances hepatic metastases of Colon Cancer via monocyte chemoattractant Protein-1-mediated inflammatory cell infiltration, J. Biol. Chem., 290, 10667, 10.1074/jbc.M114.612622 Piao, 2018, Complement 5a stimulates macrophage polarization and contributes to tumor metastases of colon cancer, Exp. Cell Res., 366, 127, 10.1016/j.yexcr.2018.03.009 Nielsen, 2016, Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis, Nat. Cell Biol., 18, 549, 10.1038/ncb3340 Lim, 2015, Cd11b(+) myeloid cells support hepatic metastasis through down-regulation of angiopoietin-like 7 in cancer cells, Hepatology, 62, 521, 10.1002/hep.27838 Lim, 2016, Targeting the CCL2-CCR2 signaling axis in cancer metastasis, Oncotarget, 7, 28697, 10.18632/oncotarget.7376 Zhang, 2018, Hypoxia-inducible factor-1alpha/interleukin-1beta signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment, Hepatology, 67, 1872, 10.1002/hep.29681 Qi, 2004, Impact of cirrhosis on the development of experimental hepatic metastases by B16F1 melanoma cells in C57BL/6 mice, Hepatology, 40, 1144, 10.1002/hep.20421 Ohashi, 2019, NOD-like receptor C4 inflammasome regulates the growth of Colon Cancer liver metastasis in NAFLD, Hepatology, 70, 1582, 10.1002/hep.30693 van de Laar, 2016, Yolk sac macrophages, fetal liver, and adult monocytes can colonize an empty niche and develop into functional tissue-resident macrophages, Immunity, 44, 755, 10.1016/j.immuni.2016.02.017 Pyonteck, 2013, CSF-1R inhibition alters macrophage polarization and blocks glioma progression, Nat. Med., 19, 1264, 10.1038/nm.3337 Zhu, 2017, Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression, Immunity, 47, 597, 10.1016/j.immuni.2017.08.018 Ostrand-Rosenberg, 2009, Myeloid-derived suppressor cells: linking inflammation and cancer, J. Immunol., 182, 4499, 10.4049/jimmunol.0802740 Gabrilovich, 2009, Myeloid-derived suppressor cells as regulators of the immune system, Nat. Rev. Immunol., 9, 162, 10.1038/nri2506 Gabrilovich, 2012, Coordinated regulation of myeloid cells by tumours, Nat. Rev. Immunol., 12, 253, 10.1038/nri3175 Kusmartsev, 2004, Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species, J. Immunol., 172, 989, 10.4049/jimmunol.172.2.989 Keskinov, 2014, Myeloid regulatory cells in tumor spreading and metastasis, Immunobiology Huang, 2006, Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host, Cancer Res., 66, 1123, 10.1158/0008-5472.CAN-05-1299 Sade-Feldman, 2013, Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation, Immunity, 38, 541, 10.1016/j.immuni.2013.02.007 Condamine, 2011, Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function, Trends Immunol., 32, 19, 10.1016/j.it.2010.10.002 Katoh, 2013, CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis, Cancer Cell, 24, 631, 10.1016/j.ccr.2013.10.009 Zhao, 2014, Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model, Lab. Invest., 94, 182, 10.1038/labinvest.2013.139 Binnewies, 2018, Understanding the tumor immune microenvironment (TIME) for effective therapy, Nat. Med., 24, 541, 10.1038/s41591-018-0014-x Dong, 2015, 17beta-estradiol contributes to the accumulation of myeloid-derived suppressor cells in blood by promoting TNF-alpha secretion, Acta Biochim Biophys Sin (Shanghai), 47, 620, 10.1093/abbs/gmv053 Ham, 2015, TNF Receptor-2 facilitates an immunosuppressive microenvironment in the liver to promote the colonization and growth of hepatic metastases, Cancer Res., 75, 5235, 10.1158/0008-5472.CAN-14-3173 Wang, 2017, CXCL1 is critical for premetastatic niche formation and metastasis in colorectal Cancer, Cancer Res., 77, 3655, 10.1158/0008-5472.CAN-16-3199 Lin, 2019, The mechanism of the premetastatic niche facilitating colorectal cancer liver metastasis generated from myeloid-derived suppressor cells induced by the S1PR1-STAT3 signaling pathway, Cell Death Dis., 10, 693, 10.1038/s41419-019-1922-5 Gabrilovich, 2017, Myeloid-derived suppressor cells, Cancer Immunol. Res., 5, 3, 10.1158/2326-6066.CIR-16-0297 Hadrup, 2013, Effector CD4 and CD8 T cells and their role in the tumor microenvironment, Cancer Microenviron., 6, 123, 10.1007/s12307-012-0127-6 Petronilho, 2007, Gastrin-releasing peptide receptor as a molecular target for inflammatory diseases, Inflamm. Allergy Drug Targets, 6, 197, 10.2174/187152807783334319 Chanmee, 2014, Tumor-associated macrophages as major players in the tumor microenvironment, Cancers (Basel), 6, 1670, 10.3390/cancers6031670 Kim, 2016, Tumor-associated macrophages and neutrophils in tumor microenvironment, Mediators Inflamm., 2016, 6058147, 10.1155/2016/6058147 van Huizen, 2019, Up-regulation of collagen proteins in colorectal liver metastasis compared with normal liver tissue, J. Biol. Chem., 294, 281, 10.1074/jbc.RA118.005087 Burnier, 2011, Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis, Oncogene, 30, 3766, 10.1038/onc.2011.89 Vaniotis, 2018, Collagen IV-conveyed signals can regulate chemokine production and promote liver metastasis, Oncogene, 37, 3790, 10.1038/s41388-018-0242-z Naba, 2014, Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver, BMC Cancer, 14, 518, 10.1186/1471-2407-14-518 Yuzhalin, 2018, A core matrisome gene signature predicts cancer outcome, Br. J. Cancer, 118, 435, 10.1038/bjc.2017.458 Batlle, 2019, Transforming growth factor-beta signaling in immunity and Cancer, Immunity, 50, 924, 10.1016/j.immuni.2019.03.024 Erler, 2006, Lysyl oxidase is essential for hypoxia-induced metastasis, Nature, 440, 1222, 10.1038/nature04695 Li, 2019, Lysyl oxidase promotes liver metastasis of gastric cancer via facilitating the reciprocal interactions between tumor cells and cancer associated fibroblasts, EBioMedicine, 49, 157, 10.1016/j.ebiom.2019.10.037 Umezaki, 2019, Lysyl oxidase induces epithelial-mesenchymal transition and predicts intrahepatic metastasis of hepatocellular carcinoma, Cancer Sci., 110, 2033, 10.1111/cas.14010 Yuzhalin, 2018, Colorectal cancer liver metastatic growth depends on PAD4-driven citrullination of the extracellular matrix, Nat. Commun., 9, 4783, 10.1038/s41467-018-07306-7 Anfray, 2019, Current strategies to target tumor-associated-Macrophages to improve anti-tumor immune responses, Cells, 9, 10.3390/cells9010046 Gordon, 2017, PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity, Nature, 545, 495, 10.1038/nature22396 Meyer, 2014, Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab, Cancer Immunol. Immunother., 63, 247, 10.1007/s00262-013-1508-5 Nakasone, 2012, Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance, Cancer Cell, 21, 488, 10.1016/j.ccr.2012.02.017 Santegoets, 2014, Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab, J. Immunother. Cancer, 2, 31, 10.1186/s40425-014-0031-3 Shojaei, 2007, Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells, Nat. Biotechnol., 25, 911, 10.1038/nbt1323 Zhang, 2016, Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine, Cancer Lett., 381, 305, 10.1016/j.canlet.2016.08.004 Fleming, 2018, Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression, Front. Immunol., 9, 398, 10.3389/fimmu.2018.00398 Ries, 2014, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy, Cancer Cell, 25, 846, 10.1016/j.ccr.2014.05.016 Dowlati, 2017, A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors, J. Clin. Oncol., 35, 10.1200/JCO.2017.35.15_suppl.2523 Gomez-Roca, 2019, Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages, Ann. Oncol., 30, 1381, 10.1093/annonc/mdz163 Lee, 2020, A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors, Invest. New Drugs, 38, 99, 10.1007/s10637-019-00745-z Papadopoulos, 2017, First-in-Human study of AMG 820, a monoclonal anti-colony-Stimulating factor 1 receptor antibody, in patients with advanced solid tumors, Clin. Cancer Res., 23, 5703, 10.1158/1078-0432.CCR-16-3261 Cassier, 2019, A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), J. Clin. Oncol., 37, 2579, 10.1200/JCO.2019.37.15_suppl.2579 Vincent, 2010, 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity, Cancer Res., 70, 3052, 10.1158/0008-5472.CAN-09-3690 Germano, 2013, Role of macrophage targeting in the antitumor activity of trabectedin, Cancer Cell, 23, 249, 10.1016/j.ccr.2013.01.008 Borgoni, 2018, Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype, Oncoimmunology, 7, e1393596, 10.1080/2162402X.2017.1393596 Kusmartsev, 2003, All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination, Cancer Res., 63, 4441 Mirza, 2006, All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients, Cancer Res., 66, 9299, 10.1158/0008-5472.CAN-06-1690 Hu, 2009, Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis, Clin. Cancer Res., 15, 5485, 10.1158/1078-0432.CCR-08-2491 Pienta, 2013, Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer, Invest. New Drugs, 31, 760, 10.1007/s10637-012-9869-8 Sandhu, 2013, A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors, Cancer Chemother. Pharmacol., 71, 1041, 10.1007/s00280-013-2099-8 Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N. Engl. J. Med., 364, 1817, 10.1056/NEJMoa1011923 Linehan, 2018, Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: correlation with blood monocyte counts, J. Clin. Oncol., 36, 10.1200/JCO.2018.36.5_suppl.92 Daniel, 2019, The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies, Semin. Cancer Biol. Benedicto, 2018, CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver, Oncol. Rep., 39, 2022 D’Alterio, 2019, Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1, J. Exp. Clin. Cancer Res., 38, 432, 10.1186/s13046-019-1420-8 Feig, 2013, Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer, Proc Natl Acad Sci U S A, 110, 20212, 10.1073/pnas.1320318110 Hidalgo, 2019, A multi-center phase IIA trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC), Annals of Oncology c, 30, xi33, 10.1093/annonc/mdz451 Jiao, 2019, Recent advances targeting CCR5 for Cancer and its role in immuno-oncology, Cancer Res., 79, 4801, 10.1158/0008-5472.CAN-19-1167 Halama, 2016, Tumoral immune cell exploitation in colorectal Cancer metastases can Be targeted effectively by Anti-CCR5 therapy in Cancer patients, Cancer Cell, 29, 587, 10.1016/j.ccell.2016.03.005 Hawila, 2017, CCR5 directs the mobilization of CD11b(+)Gr1(+)Ly6C(low) polymorphonuclear myeloid cells from the bone marrow to the blood to support tumor development, Cell Rep., 21, 2212, 10.1016/j.celrep.2017.10.104 Suarez-Carmona, 2019, CCR5 status and metastatic progression in colorectal cancer, Oncoimmunology, 8, e1626193, 10.1080/2162402X.2019.1626193 Murata, 2014, The CD47-SIRPalpha signalling system: its physiological roles and therapeutic application, J. Biochem., 155, 335, 10.1093/jb/mvu017 Yang, 2019, Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPa axis, Cancer Med., 8, 4245, 10.1002/cam4.2332 Rivera, 2015, Expression of mouse CD47 on human cancer cells profoundly increases tumor metastasis in murine models, BMC Cancer, 15, 964, 10.1186/s12885-015-1980-8 Michaels, 2018, CD47 blockade as an adjuvant immunotherapy for resectable pancreatic Cancer, Clin. Cancer Res., 24, 1415, 10.1158/1078-0432.CCR-17-2283 Vonderheide, 2020, CD40 agonist antibodies in Cancer immunotherapy, Annu. Rev. Med., 71, 47, 10.1146/annurev-med-062518-045435 Beatty, 2011, CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans, Science, 331, 1612, 10.1126/science.1198443 Buhtoiarov, 2005, CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro, J. Immunol., 174, 6013, 10.4049/jimmunol.174.10.6013 De Henau, 2016, Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells, Nature, 539, 443, 10.1038/nature20554 Guerriero, 2017, Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages, Nature, 543, 428, 10.1038/nature21409 Kaneda, 2016, PI3Kgamma is a molecular switch that controls immune suppression, Nature, 539, 437, 10.1038/nature19834 Maeda, 2019, Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages, Eur. J. Immunol., 49, 801, 10.1002/eji.201847888 Muller, 2018, Both type I and type II interferons can activate antitumor M1 macrophages when combined with TLR stimulation, Front. Immunol., 9, 2520, 10.3389/fimmu.2018.02520 Yu, 2009, STATs in cancer inflammation and immunity: a leading role for STAT3, Nat. Rev. Cancer, 9, 798, 10.1038/nrc2734 Trovato, 2019, Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3, J. Immunother. Cancer, 7, 255, 10.1186/s40425-019-0734-6 Christmas, 2018, Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs, Cancer Immunol. Res., 6, 1561, 10.1158/2326-6066.CIR-18-0070 Kim, 2014, Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells, Proc Natl Acad Sci U S A, 111, 11774, 10.1073/pnas.1410626111 Orillion, 2017, Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma, Clin. Cancer Res., 23, 5187, 10.1158/1078-0432.CCR-17-0741 Dahmani, 2018, TGF-beta in t cell biology: implications for Cancer immunotherapy, Cancers (Basel), 10, 10.3390/cancers10060194 Katz, 2016, TGF-beta signaling in liver and gastrointestinal cancers, Cancer Lett., 379, 166, 10.1016/j.canlet.2016.03.033 Tauriello, 2018, TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis, Nature, 554, 538, 10.1038/nature25492 Otegbeye, 2018, Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models, PLoS One, 13, e0191358, 10.1371/journal.pone.0191358 Melisi, 2019, A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer, J. Clin. Oncol., 37, 10.1200/JCO.2019.37.15_suppl.4124 Toor, 2019, Immune checkpoints in the tumor microenvironment, Semin. Cancer Biol. Xu, 2014, LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses, Cancer Res., 74, 3418, 10.1158/0008-5472.CAN-13-2690 Wang, 2019, Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3, Cell, 176, 334, 10.1016/j.cell.2018.11.010 Sun, 2019, The rise of NK cell checkpoints as promising therapeutic targets in Cancer immunotherapy, Front. Immunol., 10, 2354, 10.3389/fimmu.2019.02354 Krueger, 2011, Regulation of NK cell repertoire and function in the liver, Crit. Rev. Immunol., 31, 43, 10.1615/CritRevImmunol.v31.i1.40 Sun, 2017, High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer, Oncoimmunology, 6, e1264562, 10.1080/2162402X.2016.1264562 Andre, 2018, Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both t and NK cells, Cell, 175, 1731, 10.1016/j.cell.2018.10.014 Segal, 2018, First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer, J. Clin. Oncol., 36, 10.1200/JCO.2018.36.15_suppl.3540 Madan, 2007, PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma, Expert Opin. Biol. Ther., 7, 543, 10.1517/14712598.7.4.543 Madan, 2012, Clinical evaluation of TRICOM vector therapeutic cancer vaccines, Semin. Oncol., 39, 296, 10.1053/j.seminoncol.2012.02.010 Martinez, 2019, CAR t cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment, Front. Immunol., 10, 128, 10.3389/fimmu.2019.00128 Sur, 2020, Chimeric antigen receptor T-Cell therapy for colorectal Cancer, J. Clin. Med., 9, 10.3390/jcm9010182 Wagner, 2018, Colorectal cancer vaccines: tumor-associated antigens vs neoantigens, World J. Gastroenterol., 24, 5418, 10.3748/wjg.v24.i48.5418 Gulati, 2020, Current state of systemic therapies for advanced renal cell carcinoma, Curr. Oncol. Rep., 22, 26, 10.1007/s11912-020-0892-1 Murdoch, 2008, The role of myeloid cells in the promotion of tumour angiogenesis, Nat. Rev. Cancer, 8, 618, 10.1038/nrc2444 Rivera, 2015, Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy, Cell Rep., 11, 577, 10.1016/j.celrep.2015.03.055 Missiaen, 2018, The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer, Semin. Cancer Biol., 52, 107, 10.1016/j.semcancer.2018.06.002 Griffioen, 1996, Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors, Cancer Res., 56, 1111 Rivera, 2015, Intertwined regulation of angiogenesis and immunity by myeloid cells, Trends Immunol., 36, 240, 10.1016/j.it.2015.02.005 Voron, 2015, VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors, J. Exp. Med., 212, 139, 10.1084/jem.20140559 Rigamonti, 2014, Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade, Cell Rep., 8, 696, 10.1016/j.celrep.2014.06.059 Cheng, 2019, LBA3IMbrave150: efficacy and safety results from a phase III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC), Ann. Oncol., 30 Makker, 2019, Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial, Lancet Oncol., 20, 711, 10.1016/S1470-2045(19)30020-8 Rini, 2019, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N. Engl. J. Med., 380, 1116, 10.1056/NEJMoa1816714 Taylor, 2020, Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial Cancer, and other selected advanced solid tumors, J. Clin. Oncol., JCO1901598